L. Rusen

1.3k total citations
20 papers, 742 citations indexed

About

L. Rusen is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, L. Rusen has authored 20 papers receiving a total of 742 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 5 papers in Genetics and 1 paper in Molecular Biology. Recurrent topics in L. Rusen's work include Hemophilia Treatment and Research (20 papers), Blood Coagulation and Thrombosis Mechanisms (11 papers) and Platelet Disorders and Treatments (9 papers). L. Rusen is often cited by papers focused on Hemophilia Treatment and Research (20 papers), Blood Coagulation and Thrombosis Mechanisms (11 papers) and Platelet Disorders and Treatments (9 papers). L. Rusen collaborates with scholars based in United States, Romania and Poland. L. Rusen's co-authors include Toshko Lissitchkov, R. Bianco, Liselotte S. Ebbesen, M. Şerban, Barbara A. Konkle, Elisabeth Erhardtsen, Liana Gercheva, Vesselina Goranova‐Marinova, Mark T. Reding and Marilyn J. Manco‐Johnson and has published in prestigious journals such as Blood, Thrombosis and Haemostasis and Journal of Thrombosis and Haemostasis.

In The Last Decade

L. Rusen

20 papers receiving 724 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
L. Rusen United States	10	723	187	93	24	21	20	742
Claude Négrier France	13	569 0.8×	176 0.9×	67 0.7×	23 1.0×	28 1.3×	29	607
Nives Selak Bienz Switzerland	7	516 0.7×	157 0.8×	35 0.4×	30 1.3×	23 1.1×	10	536
M. Oh United States	6	592 0.8×	174 0.9×	60 0.6×	8 0.3×	15 0.7×	8	615
Sammy Chebon Switzerland	11	698 1.0×	219 1.2×	50 0.5×	41 1.7×	35 1.7×	22	731
Marianne Uguen Switzerland	7	373 0.5×	154 0.8×	45 0.5×	21 0.9×	15 0.7×	15	420
Carmen Escuriola Germany	7	491 0.7×	132 0.7×	90 1.0×	19 0.8×	10 0.5×	9	517
C. Escuriola‐Ettingshausen Germany	11	455 0.6×	129 0.7×	52 0.6×	16 0.7×	24 1.1×	22	466
F. Abdul Karim Denmark	6	350 0.5×	93 0.5×	53 0.6×	8 0.3×	15 0.7×	10	369
Glaivy Batsuli United States	8	235 0.3×	72 0.4×	36 0.4×	9 0.4×	15 0.7×	23	260
Sossana Delimpasi Greece	8	159 0.2×	85 0.5×	171 1.8×	10 0.4×	84 4.0×	13	243

Countries citing papers authored by L. Rusen

Since Specialization

Citations

This map shows the geographic impact of L. Rusen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Rusen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Rusen more than expected).

Fields of papers citing papers by L. Rusen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Rusen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Rusen. The network helps show where L. Rusen may publish in the future.

Co-authorship network of co-authors of L. Rusen

This figure shows the co-authorship network connecting the top 25 collaborators of L. Rusen. A scholar is included among the top collaborators of L. Rusen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Rusen. L. Rusen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kenet, Gili, Rolf Ljung, L. Rusen, et al.. (2020). Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study. Thrombosis Research. 189. 96–101. 3 indexed citations

Windyga, Jerzy, Oleksandra Stasyshyn, Toshko Lissitchkov, et al.. (2020). Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study. Clinical and Applied Thrombosis/Hemostasis. 26. 2874349364–2874349364. 1 indexed citations

Dargaud, Yesim, Claude Négrier, L. Rusen, et al.. (2018). Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq^®(human‐cl rhFVIII) in previously treated patients with severe haemophilia A. Haemophilia. 24(4). 619–627. 22 indexed citations

Rusen, L., Kaan Kavaklı, Joan Korth‐Bradley, et al.. (2018). Clinical experience with moroctocog alfa (AF‐CC) in younger paediatric patients with severe haemophilia A: Two open‐label studies. Haemophilia. 24(4). 604–610. 6 indexed citations

Manco‐Johnson, Marilyn J., Björn Lundin, Sharon Funk, et al.. (2017). Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis. 15(11). 2115–2124. 87 indexed citations

Lissitchkov, Toshko, L. Rusen, Pencho Georgiev, et al.. (2017). PK‐guided personalized prophylaxis with Nuwiq^® (human‐cl rhFVIII) in adults with severe haemophilia A. Haemophilia. 23(5). 697–704. 43 indexed citations

Nemes, László, Víctor Jiménez‐Yuste, L. Rusen, et al.. (2015). Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings. Thrombosis and Haemostasis. 114(10). 676–684. 6 indexed citations

Ljung, Rolf, Gili Kenet, Maria Elisa Mancuso, et al.. (2015). BAY 81‐8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial. Haemophilia. 22(3). 354–360. 25 indexed citations

Klamroth, Robert, Toshko Lissitchkov, L. Rusen, et al.. (2015). Personalized Prophylaxis with Human-Cl Recombinant FVIII in HA Patients. Blood. 126(23). 547–547. 1 indexed citations

10.

Stasyshyn, Oleksandra, T. A. Andreeva, L. Rusen, et al.. (2014). Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial. Haemophilia. 21(2). 196–203. 7 indexed citations

11.

Stasyshyn, Oleksandra, L. Rusen, M. Şerban, et al.. (2014). Safe switching from a pdFIX (Immunine^®) to a rFIX (Bax326). Haemophilia. 20(5). 674–681. 6 indexed citations

12.

Valentino, Leonard A., et al.. (2014). Multicentre, randomized, open‐label study of on‐demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia. 20(3). 398–406. 53 indexed citations

13.

Manco‐Johnson, Marilyn J., Christine L. Kempton, Mark T. Reding, et al.. (2013). Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis. 11(6). 1119–1127. 149 indexed citations

14.

Windyga, Jerzy, Toshko Lissitchkov, Oleksandra Stasyshyn, et al.. (2013). Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B. Haemophilia. 20(1). 15–24. 41 indexed citations

15.

Stasyshyn, Oleksandra, T. A. Andreeva, L. Rusen, et al.. (2013). Pharmacokinetics, Efficacy and Safety Of a Recombinant Factor IX (BAX326) In Previously-Treated Pediatric Patients < 12 Years Of Age With Severe Or Moderately Severe Hemophilia B. Blood. 122(21). 1118–1118. 1 indexed citations

16.

Windyga, Jerzy, Toshko Lissitchkov, Oleksandra Stasyshyn, et al.. (2012). Pharmacokinetics, Efficacy and Safety of BAX326, a Novel Recombinant Factor IX: A Prospective, Controlled, Multicenter Study in Previously Treated Patients with Severe (FIX Level < 1%) or Moderately Severe (FIX Level ≤ 2%) Hemophilia B.. Blood. 120(21). 2222–2222. 1 indexed citations

17.

Windyga, Jerzy, L. Rusen, Ralph A. Gruppo, et al.. (2010). BDDrFVIII (Moroctocog alfa [AF‐CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study. Haemophilia. 16(5). 731–739. 18 indexed citations

18.

Windyga, Jerzy, et al.. (2008). BDDrFVIII [moroctocog alfa (AF-CC), Xyntha] for Surgical Hemostasis in Patients with Hemophilia A: Results from a Pivotal Study.. Blood. 112(11). 1229–1229. 1 indexed citations

19.

Konkle, Barbara A., Liselotte S. Ebbesen, Elisabeth Erhardtsen, et al.. (2007). Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. Journal of Thrombosis and Haemostasis. 5(9). 1904–1913. 259 indexed citations

20.

Konkle, Barbara A., Liselotte S. Ebbesen, Ute Friedrich, et al.. (2006). Randomized, Prospective Clinical Trial of rFVIIa for Secondary Prophylaxis in Hemophilia Patients with Inhibitors.. Blood. 108(11). 766–766. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact